Who Paid My Doc
PoCP study Phase Ib of NR2B modulation in MDD
Research payments
$3,432,875
Through program year 2024, $3,432,875 in research payments was reported against PoCP study Phase Ib of NR2B modulation in MDD, across 119 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharma GmbH & Co.KG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $567,508 | 17 |
| 2023 | Research | $2,637,579 | 24 |
| 2022 | Research | $132,619 | 18 |
| 2021 | Research | $95,169 | 60 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Rajinder Shiwach Desoto, TX Named on 30 payments
- Howard Hassman Clementon, NJ Named on 22 payments
- Peter Ventre Oakland Park, FL Named on 20 payments
- Lara Shirikjian Torrance, CA Named on 6 payments
- Yaneicy Gonzalez Rojas Coral Gables, FL Named on 6 payments
- Shishuka Malhotra North Canton, OH Named on 5 payments
- Scott Bartley Richardson, TX Named on 3 payments
- Edwin Gomez Oakland Park, FL Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.